812 results on '"Di Giambenedetto, Simona"'
Search Results
2. Molecular Assay-Based Extragenital Screening for Chlamydia Trachomatis and Neisseria Gonorrhoeae in Men Who Have Sex with Men
3. Reporting a single case of cystic echinococcosis in retroperitoneal mass of uncertain origin
4. Clinical presentation of human monkeypox virus infection during the 2022 outbreak: descriptive case series from a large italian Research Hospital
5. Home Care Assistance: Has Covid-19 had an Impact on the Complex Management of HIV Patients?
6. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study
7. Pillars of long-term antiretroviral therapy success
8. Efficacy of Lamivudine plus Dolutegravir versus Dolutegravir-based Three-drugs Regimens in Virologically-suppressed People Living with HIV
9. Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV
10. HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review
11. Use of telehealth for HIV care in Italy: Are doctors and patients on the same page? A cross-sectional study
12. Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir–Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report
13. Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice
14. Sexually transmitted infections in people with multidrug-resistant HIV
15. The association between stigma and wellbeing in an Italian cohort of PLWH: The role of social support and personal factors
16. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three‐drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study
17. The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition
18. Hepatitis C virus–related factors associated WITH cognitive performance in HIV-HCV-coinfected patients
19. Necrotizing mpox with persistent microbiological positivity despite the use of tecovirimat: A case report
20. Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding
21. Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience
22. The association between stigma and wellbeing in an Italian cohort of PLWH: The role of social support and personal factors.
23. Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study
24. HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART
25. Liver fibrosis is associated with cognitive impairment in people living with HIV
26. Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy
27. Characteristics of mental health interventions in a cohort of Italian PLWH over the last five years: impact of HIV disease and outbreak of COVID-19 pandemic
28. Ventilator-associated pneumonia (VAP) and pleural empyema caused by multidrug-resistant Acinetobacter baumannii in HIV and COVID 19 infected patient: A case report
29. Rapid improvement of severe Mpox lesions with oral tecovirimat
30. Comment on: Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study
31. Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients
32. Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen
33. Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA
34. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
35. Marked decrease in acquired resistance to antiretrovirals in latest years in Italy
36. SARS-CoV-2 infection in a highly experienced person living with HIV
37. No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine--dolutegravir
38. Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype
39. EARLY USE OF TECOVIRIMAT IN A YOUNG MAN WITH SEVERE MPOX SKIN LESIONS: A CASE REPORT
40. Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy
41. Dynamics of Total and Intact HIV-1 DNA in Virologically Suppressed Patients Switching to DTG-Based or ATV-Based Dual Therapy
42. Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study
43. Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life
44. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL
45. Cognitive reserve and neuropsychological functioning in older HIV-infected people
46. Home Care Assistance: Has Covid-19 had an Impact on the Complex Management of HIV Patients?
47. Functional associations between polymorphic regions of the human 3′IgH locus and COVID-19 disease
48. Two-Drug Regimen Containing Darunavir: Metabolic Evaluation of an Old Dual Therapy.
49. HIV-Related Internalized Stigma and Patient Health Engagement Model in an Italian Cohort of People Living With HIV.
50. Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.